Regencell Bioscience Holdings Ltd. (Nasdaq: RGC) has announced a 38-for-one forward stock split, approved by its board of directors. Shareholders of record as of June 12, 2025, will receive 37 additional shares for each share held. The distribution of the additional shares is expected to occur on June 13, 2025, with trading on a split-adjusted basis commencing on June 16, 2025, pending Nasdaq approval. The move aims to enhance market liquidity and make shares more accessible to investors. The company's authorized share capital and par value remain unchanged, and there will be no alterations to its name, CUSIP, or trading symbol.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.